Search Results

There are 6522 results for: content related to: Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer

  1. You have free access to this content
    Novel therapeutics for the management of castration-resistant prostate cancer (CRPC)

    BJU International

    Volume 109, Issue 7, April 2012, Pages: 968–985, Daniel J. Lee, Eugene K. Cha, Justin M. Dubin, Himisha Beltran, Thomas F. Chromecki, Harun Fajkovic, Douglas S. Scherr, Scott T. Tagawa and Shahrokh F. Shariat

    Version of Record online : 28 OCT 2011, DOI: 10.1111/j.1464-410X.2011.10643.x

  2. You have free access to this content
    New developments in castrate-resistant prostate cancer

    BJU International

    Volume 109, Issue s6, June 2012, Pages: 22–32, N. Shore, M. Mason and Th. M. de Reijke

    Version of Record online : 4 JUN 2012, DOI: 10.1111/j.1464-410X.2012.11217.x

  3. You have free access to this content
    Clinical development of novel therapeutics for castration-resistant prostate cancer

    CA: A Cancer Journal for Clinicians

    Volume 62, Issue 5, September/October 2012, Pages: 299–308, Matthew D. Galsky, Alexander C. Small, Che-kai Tsao and William K. Oh

    Version of Record online : 24 APR 2012, DOI: 10.3322/caac.21141

  4. You have free access to this content
    Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer

    International Journal of Cancer

    Volume 133, Issue 7, 1 October 2013, Pages: 1743–1750, Ning Shao, Yang Wang, Wen Yu Jiang, Di Qiao, Shi Ge Zhang, Ye Wu, Xiang Xiang Zhang, Jiu Ling Wang, Yi Ding and Ning Han Feng

    Version of Record online : 8 APR 2013, DOI: 10.1002/ijc.28162

  5. You have full text access to this OnlineOpen article
    Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?

    Cancer Medicine

    Volume 2, Issue 2, April 2013, Pages: 243–252, Edward Cha and Eric J. Small

    Version of Record online : 24 FEB 2013, DOI: 10.1002/cam4.64

  6. Emerging treatment options for patients with castration-resistant prostate cancer

    The Prostate

    Volume 72, Issue 3, February 2012, Pages: 338–349, Daniel George and Judd W. Moul

    Version of Record online : 11 JUL 2011, DOI: 10.1002/pros.21435

  7. You have free access to this content
    Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone

    Cancer

    Volume 118, Issue 22, 15 November 2012, Pages: 5709–5718, Joel B. Nelson, Karim Fizazi, Kurt Miller, Celestia Higano, Judd W. Moul, Hideyuki Akaza, Thomas Morris, Stuart McIntosh, Kristine Pemberton and Martin Gleave

    Version of Record online : 11 JUL 2012, DOI: 10.1002/cncr.27674

  8. You have free access to this content
    Castration-resistant prostate cancer: Many treatments, many options, many challenges ahead

    Cancer

    Volume 118, Issue 10, 15 May 2012, Pages: 2583–2593, Jorge A. Garcia and Brian I. Rini

    Version of Record online : 28 OCT 2011, DOI: 10.1002/cncr.26582

  9. You have free access to this content
    Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC)

    BJU International

    Volume 110, Issue 3, August 2012, Pages: 328–335, A. Oliver Sartor and John M. Fitzpatrick

    Version of Record online : 19 JUN 2012, DOI: 10.1111/j.1464-410X.2011.10818.x

  10. You have free access to this content
    Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities

    BJU International

    Volume 110, Issue 5, September 2012, Pages: 658–667, Heather Payne, Amit Bahl, Malcolm Mason, Janis Troup and Johann De Bono

    Version of Record online : 19 MAR 2012, DOI: 10.1111/j.1464-410X.2011.10886.x

  11. You have free access to this content
    Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: The Australian perspective

    Asia-Pacific Journal of Clinical Oncology

    Volume 8, Issue 1, March 2012, Pages: 31–42, Phillip PARENTE, Francis PARNIS and Howard GURNEY

    Version of Record online : 28 FEB 2012, DOI: 10.1111/j.1743-7563.2011.01506.x

  12. You have free access to this content
    Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?

    BJU International

    Volume 115, Issue 3, March 2015, Pages: 364–372, Nicolas Mottet, Noel Clarke, Maria De Santis, Filiberto Zattoni, Juan Morote and Steven Joniau

    Version of Record online : 15 JUL 2014, DOI: 10.1111/bju.12736

  13. The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer

    The Prostate

    Volume 75, Issue 12, September 1, 2015, Pages: 1247–1254, Zhibin Chen, Ni Chen, Pengfei Shen, Jing Gong, Xiang Li, Tao Zhao, Banghua Liao, Liangren Liu, Zhenhua Liu, Xingming Zhang, Jiyan Liu, Zhufeng Peng, Xueqin Chen, Miao Xu, Haojun Gui, Peng Zhang, Qiang Wei, Qiao Zhou and Hao Zeng

    Version of Record online : 27 APR 2015, DOI: 10.1002/pros.23005

  14. You have free access to this content
    Role of targeted therapy in the treatment of advanced prostate cancer

    BJU International

    Volume 105, Issue 6, March 2010, Pages: 748–767, Karim Fizazi, Cora N. Sternberg, John M. Fitzpatrick, R. William Watson and Majid Tabesh

    Version of Record online : 25 FEB 2010, DOI: 10.1111/j.1464-410X.2010.09236.x

  15. You have free access to this content
    The role of docetaxel based therapy for prostate cancer in the era of targeted medicine

    International Journal of Urology

    Volume 17, Issue 3, March 2010, Pages: 228–240, Guru Sonpavde and Cora N Sternberg

    Version of Record online : 19 JAN 2010, DOI: 10.1111/j.1442-2042.2010.02449.x

  16. You have free access to this content
    Role of Immunotherapy in Castration-Resistant Prostate Cancer (CRPC)

    BJU International

    Volume 113, Issue 3, March 2014, Pages: 367–375, Cristina Suárez, Rafael Morales-Barrera, Victor Ramos, Isaac Núñez, Claudia Valverde, Jacques Planas, Juan Morote, Xavier Maldonado and Joan Carles

    Version of Record online : 12 APR 2013, DOI: 10.1111/bju.12110

  17. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer

    The Prostate

    Volume 75, Issue 6, May 1, 2015, Pages: 616–627, Yixuan Gong, Uma D. Chippada-Venkata, Matthew D. Galsky, Jiaoti Huang and William K. Oh

    Version of Record online : 5 JAN 2015, DOI: 10.1002/pros.22945

  18. Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer

    The Prostate

    Volume 75, Issue 7, May 15, 2015, Pages: 777–782, Gang Wu, Shengsong Huang, Kent L. Nastiuk, Jinliang Li, Jun Gu, Ming Wu, Qimin Zhang, Hanqing Lin and Denglong Wu

    Version of Record online : 1 MAR 2015, DOI: 10.1002/pros.22967

  19. You have free access to this content
    Immunotherapy for prostate cancer: the next step?

    Trends in Urology & Men's Health

    Volume 7, Issue 2, March/April 2016, Pages: 28–32, Hannah Rush, Clare Gilson and Simon Chowdhury

    Version of Record online : 4 APR 2016, DOI: 10.1002/tre.514

  20. You have free access to this content
    Current and emerging treatment modalities for metastatic castration-resistant prostate cancer

    BJU International

    Volume 107, Issue s2, April 2011, Pages: 13–20, Sergio Bracarda, Christopher Logothetis, Cora N. Sternberg and Stéphane Oudard

    Version of Record online : 7 MAR 2011, DOI: 10.1111/j.1464-410X.2010.10036.x